Is Aquestive Therapeutics, Inc. (AQST) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 7.4% / 30% | 13.9% / 30% | 1.4% / 30% | 5.97% / 5% | ✗ NOT HALAL |
| DJIM | 7.4% / 33% | 13.9% / 33% | 1.4% / 33% | 5.97% / 5% | ✗ NOT HALAL |
| MSCI | 37.5% / 33% | 70.5% / 33% | 7.2% / 33% | 5.97% / 5% | ✗ NOT HALAL |
| S&P | 7.4% / 33% | 13.9% / 33% | 1.4% / 33% | 5.97% / 5% | ✗ NOT HALAL |
| FTSE | 37.5% / 33% | 70.5% / 33% | 7.2% / 50% | 5.97% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 58.3% | |
| Operating Margin | -221.6% | |
| Net Margin | -188.1% | |
| Return on Assets (ROA) | -33.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$52M |
| Free Cash Flow | -$53M |
| Total Debt | $42M |
| Current Ratio | 3.1 |
| Total Assets | $160M |
Price & Trading
| Last Close | $4.14 |
| 50-Day MA | $3.87 |
| 200-Day MA | $4.79 |
| Avg Volume | 4.9M |
| Beta | 1.6 |
|
52-Week Range
$2.12
| |
About Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Aquestive Therapeutics, Inc. (AQST) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Aquestive Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Aquestive Therapeutics, Inc.'s debt ratio?
Aquestive Therapeutics, Inc.'s debt ratio is 7.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 37.5%.
What are Aquestive Therapeutics, Inc.'s key financial metrics?
Aquestive Therapeutics, Inc. has a market capitalization of $491M, and revenue of $45M. The company maintains a gross margin of 58.3% and a net margin of -188.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.